Michael Cherny
Stock Analyst at Leerink Partners
(4.22)
# 508
Out of 4,761 analysts
135
Total ratings
58.33%
Success rate
12.56%
Average return
Main Sectors:
Stocks Rated by Michael Cherny
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CVS CVS Health | Upgrades: Outperform | $55 → $75 | $63.48 | +18.15% | 11 | Feb 13, 2025 | |
| PGNY Progyny | Maintains: Buy | $21 → $25 | $23.20 | +7.76% | 10 | Feb 11, 2025 | |
| DOCS Doximity | Upgrades: Outperform | $60 → $90 | $72.37 | +24.36% | 2 | Feb 7, 2025 | |
| ACCD Accolade | Downgrades: Market Perform | n/a | $6.93 | - | 8 | Jan 8, 2025 | |
| MCK McKesson | Maintains: Buy | $680 → $650 | $597.71 | +8.75% | 11 | Jan 6, 2025 | |
| ALGN Align Technology | Upgrades: Outperform | $235 → $280 | $190.43 | +47.04% | 2 | Jan 6, 2025 | |
| DGX Quest Diagnostics | Upgrades: Outperform | $135 → $174 | $172.24 | +1.02% | 2 | Jan 6, 2025 | |
| CAH Cardinal Health | Upgrades: Buy | $132 → $145 | $127.06 | +14.12% | 10 | Jan 6, 2025 | |
| HSIC Henry Schein | Upgrades: Buy | $69 → $84 | $77.24 | +8.75% | 2 | Jan 6, 2025 | |
| PDCO Patterson Companies | Downgrades: Market Perform | $29 → $31 | $31.07 | +0.90% | 24 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $260 → $248 | $191.04 | +29.82% | 2 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $270 → $255 | $201.39 | +26.62% | 3 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $18.75 | - | 8 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Perform | $16 → $23 | $20.87 | +10.21% | 10 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $23 → $25 | $49.28 | -49.27% | 9 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $277 → $275 | $241.43 | +13.90% | 3 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $1.96 | +1,175.51% | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $23 → $22 | $10.16 | +116.54% | 2 | Mar 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $260 | $249.85 | +4.06% | 1 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $23 | $18.61 | +20.90% | 5 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $8 | $4.81 | +66.32% | 5 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $19 | $13.17 | +44.27% | 1 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $17 | $11.51 | +47.70% | 1 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $113 → $53 | $17.94 | +192.64% | 2 | Jan 5, 2022 |
CVS Health
Feb 13, 2025
Upgrades: Outperform
Price Target: $55 → $75
Current: $63.48
Upside: +18.15%
Progyny
Feb 11, 2025
Maintains: Buy
Price Target: $21 → $25
Current: $23.20
Upside: +7.76%
Doximity
Feb 7, 2025
Upgrades: Outperform
Price Target: $60 → $90
Current: $72.37
Upside: +24.36%
Accolade
Jan 8, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $6.93
Upside: -
McKesson
Jan 6, 2025
Maintains: Buy
Price Target: $680 → $650
Current: $597.71
Upside: +8.75%
Align Technology
Jan 6, 2025
Upgrades: Outperform
Price Target: $235 → $280
Current: $190.43
Upside: +47.04%
Quest Diagnostics
Jan 6, 2025
Upgrades: Outperform
Price Target: $135 → $174
Current: $172.24
Upside: +1.02%
Cardinal Health
Jan 6, 2025
Upgrades: Buy
Price Target: $132 → $145
Current: $127.06
Upside: +14.12%
Henry Schein
Jan 6, 2025
Upgrades: Buy
Price Target: $69 → $84
Current: $77.24
Upside: +8.75%
Patterson Companies
Dec 11, 2024
Downgrades: Market Perform
Price Target: $29 → $31
Current: $31.07
Upside: +0.90%
Nov 19, 2024
Reiterates: Outperform
Price Target: $260 → $248
Current: $191.04
Upside: +29.82%
Nov 19, 2024
Reiterates: Outperform
Price Target: $270 → $255
Current: $201.39
Upside: +26.62%
Nov 7, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $18.75
Upside: -
Oct 31, 2024
Upgrades: Market Perform
Price Target: $16 → $23
Current: $20.87
Upside: +10.21%
Oct 21, 2024
Maintains: Buy
Price Target: $23 → $25
Current: $49.28
Upside: -49.27%
Oct 7, 2024
Maintains: Outperform
Price Target: $277 → $275
Current: $241.43
Upside: +13.90%
Apr 22, 2024
Initiates: Outperform
Price Target: $25
Current: $1.96
Upside: +1,175.51%
Mar 18, 2024
Maintains: Market Perform
Price Target: $23 → $22
Current: $10.16
Upside: +116.54%
Feb 26, 2024
Initiates: Outperform
Price Target: $260
Current: $249.85
Upside: +4.06%
Feb 26, 2024
Initiates: Market Perform
Price Target: $23
Current: $18.61
Upside: +20.90%
Feb 26, 2024
Initiates: Outperform
Price Target: $8
Current: $4.81
Upside: +66.32%
Feb 26, 2024
Initiates: Market Perform
Price Target: $19
Current: $13.17
Upside: +44.27%
Feb 26, 2024
Initiates: Market Perform
Price Target: $17
Current: $11.51
Upside: +47.70%
Jan 5, 2022
Downgrades: Underperform
Price Target: $113 → $53
Current: $17.94
Upside: +192.64%